💙 Daddy
I read a lot of science papers. A lot. Mostly late at night. What you'll find here is a curated set of the most important studies behind Kenzo's protocol — explained in plain language, with evidence ratings and direct links to the original research. These summaries are meant to help you have better conversations with your doctors, not to replace them.
💗 Mama
I used to feel intimidated by research papers. Jay would summarize them for me, and I'd ask follow-up questions. Over time, I started reading them myself. You don't need a science degree — you need curiosity and the right doctor to talk it through with. Use this page as your starting point.
📚 How to use this
Each study is summarized in everyday language with an evidence rating. Strong means high-quality evidence (a randomized controlled trial, a large sample, or a meta-analysis). Moderate means well-designed but smaller, open-label (no placebo group), or not yet widely replicated. These ratings reflect study quality, not our personal endorsement. Where a study has important limitations, we note them — good science means stating what a study doesn't show, too. Always consult your doctor.
🧭 Where the evidence stands
Last reviewed: April 2026
This is an active, fast-moving area of science, and the picture has shifted recently. We update this page as things change — and we think you deserve the honest, current state of it, not just the hopeful version. A few important developments as of early 2026:
The biggest leucovorin (folinic acid) autism trial to date was retracted in January 2026 after independent reviewers couldn't reproduce its results. It didn't sort children by FRAA status, so it bears mostly on the broad "leucovorin for all autism" claim rather than the narrower, antibody-guided rationale — but it does remove what had been the largest single piece of supporting evidence.
The U.S. FDA approved leucovorin only for the rare, genetically-confirmed form of cerebral folate deficiency (FOLR1) in March 2026 — and specifically declined to approve it for autism in general, citing insufficient evidence. (Importantly, "not FDA-approved for autism" is not the same as "banned" — doctors can still prescribe it case by case; the FDA simply hasn't put its formal stamp on that use.)
Major medical bodies — including the American Academy of Pediatrics and the Child Neurology Society — do not endorse routine leucovorin use for autism outside of documented cerebral folate deficiency, while supporting individual, doctor-guided decisions.
None of this erases the biology on this page: cerebral folate deficiency is real, FRAAs are more common in autistic children than in others, and there's a genuine, biologically-grounded case for a careful, monitored trial of folinic acid in a child who tests positive — especially for the binding antibody, which one 2024 study linked to better treatment response. What it does mean is that the science is genuinely still being settled. Several larger, FRAA-stratified trials are expected to report during 2026, and they may sharpen the picture in either direction. The honest, useful posture — for us and for you — is to treat these interventions as careful experiments with your own doctor: clear goals, a set timeframe, and an honest look at whether they actually helped your child.
Cerebral Folate Deficiency & FRAAs
The foundational research behind FRAA testing and leucovorin treatment in ASD.
Ramaekers VT, Rothenberg SP, Sequeira JM, et al. — New England Journal of Medicine, 2005
The foundational paper that identified FRAAs as a cause of cerebral folate deficiency and showed that leucovorin treatment could normalize brain folate levels. Published in one of the world's most rigorous medical journals.
Frye RE, Sequeira JM, Quadros EV, James SJ, Rossignol DA — Molecular Psychiatry, 2013
In this group of 93 children with ASD, roughly 60% tested positive for blocking FRAAs and 44% for binding FRAAs — far above the rates seen in children without autism, establishing CFD as one of the more prevalent and potentially treatable biomedical findings in autism. In an open-label treatment arm, children positive for FRAAs who received leucovorin showed improvements in verbal communication, language, and attention.
Frye RE, Slattery J, Delhey L, et al. — Molecular Psychiatry, 2018
A randomized, double-blind, placebo-controlled trial of high-dose folinic acid (leucovorin) in 48 children with ASD and language impairment. Children who received it showed significantly greater improvement in verbal communication than those on placebo (a medium-to-large effect, Cohen's d = 0.70). The effect was strongest in the subgroup who tested positive for FRAAs (a large effect, Cohen's d = 0.91) — which is why FRAA status is used to predict who is most likely to respond. This is the strongest piece of evidence behind the folinic acid in Kenzo's protocol.
Worth knowing: the authors call this a small, single-site trial and describe the findings as preliminary until confirmed in larger multi-center studies. The largest benefit was in a subgroup (FRAA-positive), not the whole group. Larger trials are underway and expected to report during 2026.
Frye RE, McCarty PJ, Werner BA, et al. — Journal of Personalized Medicine, 2024
This is the study most relevant to Kenzo's specific result. Looking back at 110 children with ASD who were tested for FRAAs and treated with leucovorin, the researchers found that children with higher levels of the binding antibody tended to respond better to treatment — improving more on standard measures of social and disruptive behavior. It's a key reason the binding antibody (Kenzo's positive result) is treated as a meaningful, treatment-relevant finding, not a lesser one.
Worth knowing: this was a retrospective analysis (looking back at clinic records, not a planned controlled trial), so it shows a useful association rather than proof. A positive FRAA test is also not a diagnosis on its own — the antibody appears in some children without autism too, and levels can change over time — so it's best read as one input your doctor weighs, alongside symptoms and other tests.
Ramaekers VT, Quadros EV — Nutrients, 2022
A clinical review arguing that early intervention matters: the authors report that outcomes in FRAA-related CFD are closely tied to how early high-dose folinic acid is started and brain folate is restored, which is part of why they emphasize early screening.
Methylation, Glutathione & Oxidative Stress
Research mapping out metabolic vulnerabilities, detoxification deficits, and antioxidant depletion in autism — much of it led by Dr. S. Jill James and Dr. Richard Frye.
💙 Daddy
I find it helpful to think of this as a three-part system — though one thing surprised me when I dug in: these researchers aren't separate camps, they actually collaborate, and Dr. Frye is the common thread through most of these studies.
Dr. Richard Frye provides the Fuel — folinic acid, the form of folate that can reach the brain by routing around a blocked receptor.
The Spark is methylation. Methyl-B12 is the cofactor that lets the folate-charged cycle run: it allows the enzyme methionine synthase to work, which in turn feeds the production of SAMe — the molecule the body uses to "write" the methylation marks involved in gene regulation, neurotransmitter production, and building myelin (the insulation around nerve fibers). Dr. S. Jill James mapped much of this methylation and glutathione biochemistry in autism. (Whether better myelination translates into specific language gains is a reasonable idea, but it's not something these studies set out to prove — so I hold it as a working theory, not a settled fact.)
Dr. Richard Boles provides the Engine — mitochondrial support. A healthy methylation cycle also feeds the body's own production of glutathione, its master antioxidant, which protects the mitochondria and helps the whole system run more stably.
One honest note: much of this targeted-treatment research comes from a small group of researchers, and some of it is early or industry-supported. The underlying biochemistry is well-established; whether a given supplement changes a given child's day-to-day is exactly what a careful, measured trial with your doctor is for. See the "Where the evidence stands" note near the top of this page.
Hendren RL, James SJ, Widjaja F, et al. — Journal of Child and Adolescent Psychopharmacology, 2016
A double-blind, randomized, placebo-controlled trial of injected (subcutaneous) methyl-B12. Children who received it showed significant improvement on a clinician-rated overall measure (CGI-I), and that improvement tracked a measurable rise in the body's methylation capacity (the SAM/SAH ratio) — linking the clinical change to the underlying biochemistry.
Worth knowing: the parent-rated scales (ABC, SRS) did not reach statistical significance — only the clinician-rated measure did. And it used injection, not oral drops; oral and sublingual B12 are absorbed less reliably, so this trial doesn't directly tell you how a given oral dose will perform.
Frye RE, Melnyk S, Fuchs G, et al. — Autism Research and Treatment, 2013
In 37 children, combining methyl-B12 and folinic acid for three months was associated with improvements across all Vineland adaptive-behavior subscales (average effect size 0.59), and the children whose glutathione redox status improved most tended to show the largest gains in communication, daily-living, and social skills — tying the biochemistry to the behavior.
Worth knowing: this was an open-label study — there was no placebo group, so improvements over time can't be cleanly separated from expectation or natural development. It's supportive, not confirmatory.
James SJ, Cutler P, Melnyk S, et al. — American Journal of Clinical Nutrition, 2004
The landmark study that first showed many children with autism have, as a group, lower methylation capacity and lower levels of reduced glutathione (the body's master antioxidant) than typically developing children — establishing a biological link between redox/methylation imbalance and ASD that much of the later treatment research builds on.
Worth knowing: this is a case-control comparison describing group averages — it documents an association, not a cause, and not every child with autism shows this pattern (Kenzo's own baseline glutathione marker, for instance, was normal).
James SJ, Melnyk S, Fuchs G, et al. — American Journal of Clinical Nutrition, 2009
An intervention trial (the precursor to the 2013 adaptive-behavior paper above) showing that high-dose injected methyl-B12 combined with oral folinic acid measurably improved methylation and replenished active glutathione reserves in children with autism — demonstrating that these metabolic imbalances are responsive to treatment.
Worth knowing: this was an open-label trial (no placebo group), so it shows the biochemistry can shift with treatment, but can't by itself prove the supplement caused behavioral change.
Mitochondrial Dysfunction in ASD
The evidence base for evaluating and addressing cellular energy production in children with ASD.
Rossignol DA, Frye RE — Molecular Psychiatry, 2012
A meta-analysis finding that mitochondrial dysfunction is present in a subset of children with ASD at rates far above the general population. A key point: in most ASD cases this appears to be a secondary dysfunction (not a primary genetic disease), which raises the possibility that it may be addressable. Biomarkers including lactate and pyruvate were abnormal more often in the ASD group.
Frye RE, Rincon N, McCarty PJ, et al. — Neurobiology of Disease, 2024
An updated review of 204 studies confirming that several mitochondrial biomarkers — including lactate, pyruvate, and creatine kinase — are abnormal in more than a quarter of children with ASD, and that these abnormalities tend to correlate with language and social difficulties. It also notes that treatments targeting mitochondria (such as carnitine and ubiquinol) have shown benefit in controlled studies.
Hill Z, McCarty PJ, Boles RG, Frye RE — International Journal of Molecular Sciences, 2025
A double-blind, placebo-controlled crossover trial of a targeted mitochondrial nutrient blend (the kind of formula behind products like SpectrumNeeds). It found the supplement partly normalized mitochondrial enzyme activity and made cellular respiration more resilient to oxidative stress, alongside improvements on several parent-rated behavioral scales — notably hyperactivity and social withdrawal.
Worth knowing: this was a small trial (16 children), and the supplement was provided by its maker — so it's promising but preliminary. The gains were parent-rated; most clinician-rated measures and caregiver strain did not change significantly. A normal mitochondrial workup (e.g. on an OAT or MitoSwab) is a reasonable thing to confirm before assuming this kind of support is needed.
The Organic Acids Test (OAT) in ASD
The clinical context for metabolic urine testing in children with ASD — and how to read it carefully.
Background drawn from metabolic reviews (e.g. Frye RE, Rossignol DA) and commercial lab documentation — see linked overview
A body of clinical work describes children with ASD frequently showing abnormal organic-acid patterns in urine — markers of mitochondrial stress (such as elevated lactate or pyruvate), oxidative strain, and gut-microbial byproducts (including Clostridia-related compounds). The OAT is used in biomedical evaluation as a non-invasive, exploratory window into metabolism.
Worth knowing: the OAT is a screening tool, not a diagnosis. Many markers are sensitive to diet, recent intake, hydration, and the timing of the sample, and several are vitamin catabolites whose interpretation is debated. Independent reviews have noted its diagnostic accuracy in autism is not well-established and that reference ranges are often lab-derived. A single reading — high or low — is best read by a clinician alongside symptoms and confirmatory tests, not acted on in isolation. High values in a pathway generally carry more weight than uniformly low ones, which often reflect diet or low output.
Dietary Interventions & The Gut-Brain Axis
Mechanistic research on intestinal permeability, neuroinflammation, and dietary modifications (GFCF, Soy-free) in children with ASD.
Rose S, Bennuri SC, Davis JE, Wynne R, MacFabe DF, Frye RE, et al. — PLOS One, 2017
This study offers part of the biochemical rationale for the gut-brain-mitochondria connection. It found differences in mitochondrial function in the gut lining of children with autism, and other work links gut-microbial byproducts (such as propionic acid) to effects on mitochondrial function — which, combined with increased intestinal permeability, is one proposed pathway by which diet and the gut may influence inflammation and behavior.
Worth knowing: this is mechanistic/biological evidence about how a gut-brain link could work. The role of specific dietary proteins (gluten, casein, soy) is a reasonable hypothesis built on top of it, not something this particular study proves.
Whiteley P, Haracopos D, Knivsberg AM, et al. — Nutritional Neuroscience, 2010
A two-year randomized trial of the gluten-free, casein-free diet in children with ASD reported improvements in attention, social interaction, and communication in the diet group compared to controls.
Worth knowing: the broader evidence on GFCF diets in autism is genuinely mixed — several well-controlled trials, including a careful blinded "challenge" study, have found no clear benefit on core symptoms, and one review noted a signal of more GI upset. Results vary a lot between children, and response may depend on whether a child has gut issues or sensitivities. This is an area where individual trials and a doctor's guidance matter more than any single study.
Targeted Nutritional Interventions
The science supporting Vitamin D, Omega-3s, Probiotics, Sulforaphane, and addressing Oxalate buildup.
Saad K, Abdel-Rahman AA, Elserogy YM, et al. — Journal of Child Psychology and Psychiatry, 2016
A double-blind, randomized controlled trial reporting that high-dose vitamin D supplementation improved some core symptoms of autism (such as social awareness and communication) in children who were deficient at baseline.
Worth knowing: benefits were seen in children who were vitamin-D deficient — this is an argument for correcting a deficiency, not for high-dose vitamin D in a child whose levels are already adequate.
Amminger GP, Berger GE, Schäfer MR, et al. — Biological Psychiatry, 2007
A small pilot trial reporting that omega-3 supplementation reduced hyperactivity and repetitive behaviors compared to placebo in children with autism.
Worth knowing: this was a small pilot (a handful of children per group), and later, larger omega-3 trials in autism have had mixed results. Omega-3s are low-risk and relevant to brain health, but the evidence for a behavioral effect is modest.
Santocchi E, Guiducci L, Prosperi M, et al. — Frontiers in Psychiatry, 2020
A randomized trial finding that a multi-strain probiotic reduced GI symptoms and was associated with improvements in some sensory and core autism measures, with the clearest effects in children who also had gastrointestinal symptoms.
Worth knowing: probiotic effects in autism vary by strain and by child, and the strongest signals tend to be for GI symptoms rather than core autism features. Which specific strains help is still an open question.
Singh K, Connors SL, Macklin EA, et al. — Proceedings of the National Academy of Sciences (PNAS), 2014
A placebo-controlled, double-blind study by Johns Hopkins and Harvard researchers reporting that sulforaphane (a compound from broccoli sprouts) improved social interaction, behavior, and verbal communication, thought to work by activating cellular stress-response and antioxidant pathways.
Worth knowing: this trial studied 40 teenage and young-adult males, not young children, and was relatively small. Later, larger pediatric trials have had more mixed results, and the original study noted two seizures in the treatment group — so it's worth discussing seizure history with your doctor. It's an influential study, but its findings don't automatically transfer to a young child like Kenzo.
Konstantynowicz J, Porowski T, Zoch-Zwierz W, et al. — European Journal of Paediatric Neurology, 2012
This study found that children with ASD had, on average, higher oxalate levels in urine and blood than peers, and raised the hypothesis that impaired oxalate handling might contribute to symptoms in a subset of children.
Worth knowing: this shows an association, not that oxalate causes autism symptoms, and low-oxalate diets in autism are not well-studied. It's a reason to be aware of oxalate, not strong evidence for any specific dietary change.
🚀 More coming
We're adding studies on CoQ10 and carnitine. If there's a specific study you'd like covered, reach out through the community.
You've finished all 6 chapters!
Try the Free ATEC Screener
Track your child's progress with our free 77-item Autism Treatment Evaluation Checklist — instant scoring, PDF export, and progress tracking.
Open ATEC Screener →
This website shares our personal experience and is NOT medical advice. The studies here are summarized for general understanding and may not reflect every limitation or later finding, and research in this area is still evolving. Some interventions discussed are not FDA-approved or broadly endorsed for autism. Always consult a qualified healthcare professional before starting any treatment or intervention for your child.